PET of hypoxia: Current and future perspectives

Journal of Nuclear Medicine

Volumn 53, Issue 8, 2012, Pages 1171-1174

  Carlin, Sean ^a   Humm, John L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

2 Nitroimidazole; 18F fluoromisonidazole; 64Cu ATSM; Hypoxia; PET

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE; 2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE F 18; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL F 18; FLUOROAZOMYCINARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROERYTHRONITROMIDAZOLE F 18; HX 4; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER PROGNOSIS; CANCER RADIOTHERAPY; CLINICAL PROTOCOL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG CLEARANCE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; HYPOXIA; IMAGE ANALYSIS; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR HYPOXIA;

ANOXIA; ETANIDAZOLE; HUMANS; HYDROCARBONS, FLUORINATED; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TRIAZOLES;

EID: 84864762386     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.099770     Document Type: Review

References (25)

1. Chitneni SK, Palmer GM, Zalutsky MR, Dewhirst MW. Molecular imaging of hypoxia. J Nucl Med. 2011;52:165-168.
2. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
3. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-242.
4. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol. 2010;97:172-175.
5. Wang W, Georgi JC, Nehmeh SA, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol. 2009;54:3083-3099.
6. 18F- fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors. J Nucl Med. 2011;52:437-444.
7. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S. (Pubitemid 351948041)
8. 18F]FAZA: first small animal PET results. J Pharm Pharm Sci. 2007;10:203-211.
9. 18F-FAZA). Eur J Nucl Med Mol Imaging. 2009;36:1565-1573.
10. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160. (Pubitemid 27339632)
11. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009;53:193-200.
12. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. Nucl Med Biol. 2005;32:623-630. (Pubitemid 40981818)
13. 64Cu(II)- diacetyl-bis(N4- methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493-1502.
14. Chia K, Fleming IN, Blower PJ. Hypoxia imaging with PET: which tracers and why? Nucl Med Commun. 2012;33:217-222.
15. Sharma R. Nitroimidazole radiopharmaceuticals in bioimaging: part I: synthesis and imaging applications. Curr Radiopharm. 2011;4:361-378.
16. 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging. 2010;37:2048-2059.
17. 18F]EF5. Mol Imaging Biol. 2012;14: 205-212.
18. 18F] HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37:1663-1668.
19. 18F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer. 2004;91:1947-1954.
20. 18F] fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
21. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11:335-340.
22. 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Dis Esophagus. 2012;25:54-61.
23. Vaupel P, Hockel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007;9:1221-1235. (Pubitemid 47080831)
24. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551-560. (Pubitemid 30317470)
25. Harada H. How can we overcome tumor hypoxia in radiation therapy? J Radiat Res (Tokyo). 2011;52:545-556.